Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.

Kaitlin RasconGoran FlajcCarmine De AngelisXinli LiuMeghana V Trivedi Ekim Ekinci

Published in: The Annals of pharmacotherapy (2018)

Ribociclib, when added to endocrine therapy, significantly improves PFS and has manageable toxicity in premenopausal/perimenopausal and postmenopausal women with HR+/HER2- advanced breast cancer.

Keyphrases

postmenopausal women
bone mineral density
breast cancer risk
squamous cell carcinoma
small cell lung cancer
oxidative stress
stem cells
body composition
cell therapy
replacement therapy
early breast cancer